Abstract
Enhancing natural killer (NK) cell cytotoxicity could lead to improved cancer immunotherapy. In this issue of Molecular Therapy, Pomeroy et al. describe an efficient method for editing the genome of primary human NK cells using CRISPR/Cas9. The authors target genes using this method to enhance NK cell anti-tumor function.
Original language | English (US) |
---|---|
Pages (from-to) | 52-63 |
Number of pages | 12 |
Journal | Molecular Therapy |
Volume | 28 |
Issue number | 1 |
DOIs | |
State | Published - Jan 8 2020 |
Bibliographical note
Publisher Copyright:© 2019 The American Society of Gene and Cell Therapy
Keywords
- ADAM17
- CRISPR
- NK cells
- PD1
- immunotherapy